Corvia Medical Secures $55 Million for Heart Failure Treatment Trial
Deal News | Jun 17, 2025 | PR Newswire Cision Corvia Medical, Inc.
Corvia Medical, Inc., a Massachusetts-based medical device company, has closed a $55 million funding round from its existing investors, including Third Rock Ventures, General Catalyst Partners, AccelMed, and Lumira Ventures. The funding will be used to complete the RESPONDER-HF international trial of the Corvia Atrial Shunt, a novel transcatheter device aimed at treating heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF). The trial, being conducted across more than 65 institutions on three continents, aims to provide the necessary data for FDA approval. With heart failure affecting over 26 million people worldwide, and HFpEF being the largest unmet need in cardiovascular medicine, the Corvia Atrial Shunt could significantly improve patient outcomes by reducing left atrial pressure and preventing heart failure events. The device received Breakthrough Device designation by the FDA in 2019. CEO George Fazio and Board Chair Paul LaViolette express confidence in progressing towards FDA approval and market introduction.
Sectors
- Healthcare
- Medical Devices
Geography
- United States – Corvia Medical is headquartered in Tewksbury, Massachusetts, and the funding round is connected to driving an FDA approval process, relevant to the U.S. market.
Industry
- Healthcare – The article focuses on Corvia Medical, which is engaged in developing medical devices for heart failure treatment, a significant area within healthcare.
- Medical Devices – Corvia Medical is involved in the development and trial of a medical device, the Corvia Atrial Shunt, which addresses heart failure.
Financials
- $55 million – The total funding raised in this round to complete the RESPONDER-HF trial and pursue FDA approval.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Corvia Medical, Inc. | Target Company | Company | A company focused on pioneering treatments for heart failure, headquartered in Tewksbury, Massachusetts. |
| Third Rock Ventures | Investor | Company | Part of the investment syndicate funding Corvia Medical's trial and FDA approval process. |
| General Catalyst Partners | Investor | Company | An existing investor aiding in funding Corvia Medical's heart failure treatment trial. |
| AccelMed | Investor | Company | Another investor contributing to the funding round for Corvia Medical. |
| Lumira Ventures | Investor | Company | Participates in funding Corvia Medical's ongoing medical trial. |
| George Fazio | CEO | Person | Chief Executive Officer of Corvia Medical, overseeing the company's strategic direction. |
| Paul LaViolette | Board Chair | Person | Board Chair of Corvia Medical, supporting the company's mission and investor relations. |